Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05613556 · ClinicalTrials.gov registry record
Monitoring Physiologic Parameters in Individuals With Diabetic Peripheral Neuropathy
A clinical trial of Diabetic Foot and Diabetic Peripheral Neuropathy, sponsored by Orpyx Medical Technologies.
- Completed
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT05613556: Completed study of Diabetic Foot and Diabetic Peripheral Neuropathy, sponsored by Orpyx Medical Technologies.
NCT05613556 is a study of Diabetic Foot and Diabetic Peripheral Neuropathy that has completed, run by Orpyx Medical Technologies. The registered enrollment target is 60 participants, below the 10,339-participant average among 30 other Diabetic Foot trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05613556, a study of Diabetic Foot and Diabetic Peripheral Neuropathy, has completed, sponsored by Orpyx Medical Technologies.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to use the Orpyx® SI Sensory Insole System (Orpyx Medical Technologies Inc., Calgary AB, Canada) ("Orpyx" or "the Company") as an adjunct to diabetic peripheral neuropathy standard of care (SOC), and observe step count, pressure, temperature, and adherence data through remote patient monitoring (RPM). This will provide insights into patient engagement and the benefits of offering remote, preventative care.
Primary Outcome
frequency and location of high-pressure plantar areas
Conditions Studied
Interventions
- DEVICE Orpyx SI® Sensory Insole System
Study Locations (1)
Ohio
- WAFL Inc / Cutting Edge Research - Circleville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2023-04-28 |
What the finished NCT05613556 record still lists
NCT05613556 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 10,339-participant average among 30 other Diabetic Foot trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Diabetic Foot appearing as the primary indexed condition, and to 1 intervention - of which Orpyx SI® Sensory Insole System is the first listed.
NCT05613556 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05613556 about?
NCT05613556 is a clinical study titled "Monitoring Physiologic Parameters in Individuals With Diabetic Peripheral Neuropathy". The primary aim of this study is to use the Orpyx® SI Sensory Insole System (Orpyx Medical Technologies Inc., Calgary AB, Canada) ("Orpyx" or "the Company") as an adjunct to diabetic peripheral neuropathy standard of care (SOC), and observe step count, pressure, temperature, and adherence data throu...
What is the current status of trial NCT05613556?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2022-04-01. Estimated completion is 2023-04-28.
What conditions does trial NCT05613556 study?
This clinical trial studies the following conditions: Diabetic Foot, Diabetic Peripheral Neuropathy.
What interventions are being tested in trial NCT05613556?
The interventions under investigation include: Orpyx SI® Sensory Insole System (DEVICE).
Who is sponsoring clinical trial NCT05613556?
This trial is sponsored by Orpyx Medical Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05613556 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05613556's enrollment target sits among peer trials
60 24th of 30 higher than 5 of 30 other Diabetic Foot trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
RECRUITING
-
Effectiveness of Remote Foot Temperature Monitoring
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI